Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 16863
Corporate User License Price USD 750
Corporate User License Price INR 50588
Site License Price USD 500
Site License Price INR 33725
Request a Quote

Report Title

Santen SAS-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Santen SAS-Pharmaceuticals & Healthcare-Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Santen SAS-Pharmaceuticals & Healthcare-Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Santen SAS-Pharmaceuticals & Healthcare-Deals and Alliances Profile



Executive Summary

Santen SAS (Santen) a subsidiary of Santen Pharmaceutical Co., Ltd. is a pharmaceutical company that develops and manufactures ophthalmic products for the healthcare market. The company products are used for the treatment of corneal and conjunctival disorders, glaucoma and ocular hypertension, retinal / uveal disorders, ocular infections / allergies, and rheumatoid arthritis. The company also supplies epochal eye drops for a range of eye diseases, including glaucoma and dry eye. It operates through its offices located in Finland, Vietnam, Japan, and People's Republic of China. The company was formerly known as Novagali Pharma S.A.S. Santen is headquartered in Kita-ku, Japan.

Santen SAS-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Santen SAS, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5

Santen SAS, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6

Santen SAS, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7

Santen SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8

Santen SAS, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9

Santen SAS, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Novagali Pharma Enters Into Distribution Agreement With Ardeo Health For Nova23041 10

Novagali Pharma Enters Into Co-Promotion Agreement With OCuSOFT For Nova23041 11

Licensing Agreements 12

Santen Extends Licensing Agreement with Eupharmed to Distribute Cationorm 12

Santen Enters into Licensing Agreement with Eupharmed For Cationorm 13

Equity Offering 14

Novagali Completes IPO Of US$30 Million 14

Acquisition 15

Santen Pharma Completes Tender Offer To Acquire Remaining 49.5% Stake In Novagali Pharma For US$67.2 Million 15

Santen SAS-Key Competitors 18

Key Employees 19

Locations And Subsidiaries 20

Head Office 20

Appendix 21

Methodology 21

About GlobalData 21

Contact Us 21

Disclaimer 21

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Santen SAS, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1

Santen SAS, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1

Santen SAS, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1

Santen SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1

Santen SAS, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5

Santen SAS, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6

Santen SAS, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7

Santen SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8

List of Tables

Santen SAS, Pharmaceuticals & Healthcare, Key Facts 1

Santen SAS, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5

Santen SAS, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6

Santen SAS, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7

Santen SAS, Deals By Therapy Area, 2010 to YTD 2016 8

Santen SAS, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9

Novagali Pharma Enters Into Distribution Agreement With Ardeo Health For Nova23041 10

Novagali Pharma Enters Into Co-Promotion Agreement With OCuSOFT For Nova23041 11

Santen Extends Licensing Agreement with Eupharmed to Distribute Cationorm 12

Santen Enters into Licensing Agreement with Eupharmed For Cationorm 13

Novagali Completes IPO Of US$30 Million 14

Santen Pharma Completes Tender Offer To Acquire Remaining 49.5% Stake In Novagali Pharma For US$67.2 Million 15

Santen SAS, Key Competitors 18

Santen SAS, Key Employees 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Santen SAS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand